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Background: Dormant leukemia stem cells (LSC) promote therapeutic resistance and leukemic progression as a
result of unbridled activation of stem cell gene expression programs. Thus, we hypothesized that 1) deregulation of
the hedgehog (Hh) stem cell self-renewal and cell cycle regulatory pathway would promote dormant human LSC
generation and 2) that PF-04449913, a clinical antagonist of the GLI2 transcriptional activator, smoothened (SMO),
would enhance dormant human LSC eradication.
Methods: To test these postulates, whole transcriptome RNA sequencing (RNA-seq), microarray, qRT-PCR, stromal
co-culture, confocal fluorescence microscopic, nanoproteomic, serial transplantation and cell cycle analyses were
performed on FACS purified normal, chronic phase (CP) chronic myeloid leukemia (CML), blast crisis (BC) phase CML
progenitors with or without PF-04449913 treatment.
Results: Notably, RNA-seq analyses revealed that Hh pathway and cell cycle regulatory gene overexpression correlated
with leukemic progression. While lentivirally enforced GLI2 expression enhanced leukemic progenitor dormancy in
stromal co-cultures, this was not observed with a mutant GLI2 lacking a transactivation domain, suggesting that GLI2
expression prevented cell cycle transit. Selective SMO inhibition with PF-04449913 in humanized stromal co-cultures and
LSC xenografts reduced downstream GLI2 protein and cell cycle regulatory gene expression. Moreover, SMO inhibition
enhanced cell cycle transit and sensitized BC LSC to tyrosine kinase inhibition in vivo at doses that spare normal HSC.
Conclusion: In summary, while GLI2, forms part of a core HH pathway transcriptional regulatory network that promotes
human myeloid leukemic progression and dormant LSC generation, selective inhibition with PF-04449913 reduces the
dormant LSC burden thereby providing a strong rationale for clinical trials predicated on SMO inhibition in combination
with TKIs or chemotherapeutic agents with the ultimate aim of obviating leukemic therapeutic resistance, persistence and
progression.
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Chronic myeloid leukemia (CML) is a myeloproliferative
disease arising from the acquisition of the Philadelphia
chromosome (Ph) by hematopoietic stem cells (HSC). This
is characterized by the reciprocal translocation between the
long arms of chromosomes 9 and 22, t (9;22) (q34;q11)
which in turn gives rise to a fusion of c-ABL and BCR to
generate the BCR-ABL fusion gene that encodes the consti-
tutively active tyrosine kinase BCR-ABL1 [1]. This results
in the modulation of several key-signaling cascades leading
to increased cell proliferation, induction of cellular trans-
formation and blockage of apoptotic pathways. In CML,
chronic phase occurs after BCR-ABL1 oncogene expression
in hematopoietic stem cells (HSCs), that can then generate
an expansion of a pool of myeloid GMP (CD34 +CD38 +
Lin−) progenitors that aberrantly acquire the capacity to
self-renew, leading to progenitor LSC generation and BC
transformation [2].
Deregulation of critical stem cell processes, such as self-
renewal and dormancy, in hematopoietic progenitors con-
tributes to the generation of leukemia stem cells (LSC) that
are impervious to therapies that target dividing cells [2-14].
In advanced human myeloid malignancies that progress
from antecedent hematologic malignancies, such as blast
crisis (BC) CML, LSC have a proclivity for becoming dor-
mant in protective niches [2,5,7,11,15-18].
Targeted therapies for the treatment of CML using tyro-
sine kinase inhibitors (TKI) that block BCR–ABL activity
have advanced in recent years to include not only imatinib
but also second-generation TKIs such as dasatinib and
nilotinib. While a striking reduction in CML-related mor-
tality has occurred in patients treated early in chronic
phase with BCR-ABL1 targeted tyrosine kinase inhibitor
(TKI) therapy, the majority of patients relapse with detect-
able BCR-ABL1 transcripts following TKI discontinuation,
which has been attributed to persistence of dormant BCR-
ABL expressing hematopoietic stem and progenitor cells
[19,20] Compelling studies, such as the STIM trial, in
which a majority of CML patients relapsed within
12 months of TKI discontinuation, suggest that new thera-
peutic strategies will be required to achieve molecular
cures [21].
Previous studies have established a role for aberrant
activation of Hh signaling in a number of solid tumors
as well as hematologic malignancies [16,17]. Hh pro-
teins (ligands) bind to the receptor patched (PTCH),
causing the release of inhibition by smoothened (SMO)
and the subsequent activation of transcription factors
GLI-1 and GLI-2 that then translocate to the nucleus
and activate their target genes [22]. As the main effec-
tors of Hh pathway signaling following SMO activation,
the GLI transcriptional factors, GLI1 and GLI2 [23,24]
promote oncogenesis through up-regulation of genes
encoding apoptosis inhibitors (e.g., Bcl-2, cFLIP) [25,26]and angiogenesis inducers (e.g., vascular endothelial
growth factor) [27-33]. Thus, GLI down-regulation
through SMO antagonism could reduce LSC mainten-
ance driven by both Hh ligand dependent and ligand in-
dependent epigenetic activation mechanisms [34,35].
In CML Hh signaling is vital for maintenance of LSC
through SMO-mediated GLI1 activation but in humans
GLI2 increases with blastic transformation [36]. Moreover,
activation of the Hh stem cell pathway agonist, smoothened
(SMO) and downstream glioma associated (GLI) zinc fin-
ger transcriptional regulators, promoted LSC maintenance
in a mouse model of CML [17]. Previously, we uncovered a
GSK3β missplicing event that prevented degradation of
both β-catenin and GLI transcription factors in serially
transplantable LSC [7]. Others studies have analyzed newly
diagnosed cases of CML and found differential activation
of Sonic Hh (SHH) signaling was seen in 50% of chronic
phase, 70% of accelerated phase and over 80% of blast crisis
cases. It was shown that auto-activation of SHH signaling
provided survival and proliferative cues in CML progenitor
cells through downstream β- catenin signaling and that by
blocking the pathway with inhibitor or neutralizing anti-
bodies, apoptosis could be induced [37].
While Hh is involved in embryonic pattern formation, in-
cluding the hemogenic endothelial to hematopoietic transi-
tion [38] it also plays a pivotal role in the maintenance of
adult neural and skin stem cell populations. However Hh
signaling may be dispensable for maintenance of normal
adult hematopoiesis [39-41] suggesting that a therapeutic
window may exist for targeting human LSC compared with
normal HSC and progenitor populations in the bone mar-
row and other hematopoietic niches.
Despite extensive transcriptional profiling of BC CML
samples [11,13,14], the cell type and context specific role of
Hh pathway activation in human LSC therapeutic resist-
ance and cell cycle deregulation had not been elucidated.
Moreover, diagnostic strategies that predict progression and
therapies capable of abrogating human LSC dormancy
while sparing normal HSC function have remained elusive.
In this study, we performed RNA-seq, humanized stromal
co-cultures, human LSC xenograft assays, lentiviral overex-
pression and multi-parameter cell cycle FACS analysis to
investigate whether 1) Hh pathway and dormancy gene ac-
tivation are biomarkers of myeloid leukemic progression
and LSC generation; 2) to determine if GLI2 drives
leukemic progenitor cell cycle deregulation in human LSC
supportive niche assays and 3) if selective inhibition of
SMO by PF-04449913 reduces niche-dependent LSC main-
tenance and therapeutic resistance in LSC in vivo models.
Methods
Bone marrow and peripheral blood banked samples
Normal cord blood and adult peripheral blood samples
were purchased from All Cells. Myeloid malignancy
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from consenting patients enrolled in Institutional Review
Board approved protocols. Human hematopoietic stem
and progenitors cells were FACS Aria purified as de-
scribed previously [42].
Whole transcriptome RNA sequencing
Progenitor cells (n = 50,000) derived from viably cryo-
preserved normal cord blood (n = 3), normal peripheral
blood (n = 3), CP CML (n = 8) and BC CML (n = 9) sam-
ples, were FACS Aria sorted directly into RLT buffer
(Qiagen) and LSC microarray studies were performed as
described previously [42]. For each sample, approxi-
mately 5 ng of total RNA was processed using smarttm
cDNA synthesis protocol with smartscribe reverse tran-
scriptase (clontech, #639536), which used a modified
oligo (dt) primer to prime the first strand synthesis reac-
tion and a template switching mechanism to generate
full length single stranded cDNAs containing the
complete 5’ end of the mRNA as well as universal prim-
ing sequences for end-to-end amplification by 20 cycles
of PCR. The resultant cDNAs were fractionated and
size-selected for fragments with 250-350 bp in length.
The amplified cDNA was subjected to Illumina paired
end library construction using NEBNext paired-end
DNA sample Prep Kit (NEB, E6000B-25). Libraries se-
quenced on Illumina HiSeq2000 instruments with the
average of approximately 163.8 million Chastity-passed
read pair with 50 bp in read length. Spearman’s rank
correlation coefficient was used as the distance metric.
To test whether the grouping in the PC plots was statis-
tically significant, permutation tests were performed by
random sampling of gene sets with a sample size equal
to our signature gene set from KEGG-annotated genes
in MSigDB. Genes were excluded if expression levels
were zero across all subjects; a total of 4617 genes
remained. We drew 5000 random sets in total. A princi-
pal components analysis was performed on each random
data set and an MANOVA model was built using the
first 3 principal components as response variables and
the group label as the predictor. A permutation p-value
was defined as the proportion of the F-statistic from the
original data set that was greater than the F-statistics
from the random sets.
Illumina platform RNA-seq read alignment, coverage
analysis and clustering: Using BWA software (version
0.5.7) [43], the Chastity-passed reads were aligned to the
human reference genome (hg19/GRch37) plus exon
junction sequences constructed from all known tran-
script models in RefSeq, EnsEMBL and known genes
from the UCSC database as described previously [44].
We used default parameter settings of BWA except for
the option –s to disable Smith-Waterman alignment.
After the alignment, the reads that aligned to exonjunctions were repositioned in the genome as large-
gapped alignments using repositioning software devel-
oped in-house. We removed adapter dimer sequences
and soft-clipped reads that contained adapter sequences.
The unambiguously aligned, filtered reads were then an-
alyzed by in-house developed gene coverage analysis
software to calculate the coverage over the total col-
lapsed exonic regions in each genes as annotated in
EnsEMBL (version 59), and the RPKM values were cal-
culated to represent the expression level of exons and
genes. We used the raw read counts for differential gene
expression analysis using DESeq (v1.4.1) in R. The mul-
tiple hypothesis testing correction of p-values from
Mann–Whitney U test was done using Benjamini-
Hochberg method in p.adjust function in R. We per-
formed unsupervised hierarchical clustering using
complete linkage on log2-transformed RPKM values that
were centered on the median. Spearman’s rank correl-
ation coefficient was used as the distance metric for
clustering samples and genes. The clustering results
were visualized using Treeview (Java Cluster software).
We used RPKM values and performed the non-negative
matrix factorization clustering using NMF (v0.5.06), Bio-
base (v2.14.0) and cluster (v1.14.2) packages in R. We
ran the NMF clustering using the default ‘brunet’
method for the NMF algorithm and set the seeding
method to default ‘random’ and performed the clustering
over 200 iterations. For the factorization rank survey,
we performed clustering using 50 iterations for our
dataset, and 25 iterations for a randomized dataset.
The visualization of the consensus matrix heatmap and
the cophenetic correlation coefficient plot was done
using the plot function in R.
Transcriptome analysis of LSC isolated from PF-04449913
and vehicle treated mice
Sample preparation, library construction and sequencing
Neonatal RAG2−/−c−/− mice transplanted intraphepti-
cally with 50,000 BC CML LSC were treated 8 weeks
later with vehicle or PF-04449913 (100 mg/kg) for
2 weeks by oral gavage. Four mice were treated with ve-
hicle and four mice were treated with SMO inhibitor
(Additional file 1: Table S3). Mice were sacrificed and
human leukemia stem cells (~50,000 cells/sample) were
sorted from the liver into RLT buffer from the Qiagen
Rneasy kit and RNA was extracted. Total RNA samples
were treated once with Ribominus kit (Invitrogen,
#A10837-08) to deplete ribosomal RNA. From the
resulting RNA whole transcriptome libraries were pre-
pared for SOLiD sequencing. Samples were sequenced
in 2 different batches to produce 50 bp fragment (i.e.
non-paired-end) reads with an average of approximately
118 million reads. Samples 1–7 were sequenced with
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quenced SOLiD v4 chemistry.
The limma method was used to test for main effects of
PF-04449913 and Dasatinib, and their synergistic inter-
action among 41 genes. Null hypotheses were rejected at
p = 0.05 significance level without adjusting for multiple
comparisons.
GSEA analysis
We filtered RNA Seq data using the raw read counts per
gene to included genes with at least 10 mapped reads in
one or more samples. A total of 13,850 protein-coding
genes were included in the analysis. The counts were nor-
malized using upper-quartile normalization. Significance
Analysis of Microarrays (SAM) was used to rank the genes
according to their differences in expression levels between
the four SMO inhibitor treated mice and the four vehicle
mice. Gene set enrichment analysis (GSEA) was used to
assess the effect of SMO treatment on cell cycle pathways.
Of the eight a priori cell cycle pathways considered in the
analysis, “Regulation of Cell Cycle” was significantly down
regulated comparing treated mice (n = 4) to control mice
(n = 4) (family-wise p value =0.02). Six additional pathways
out of the 8 total were observed to be down regulated, al-
though not significantly. Table columns are pathway name,
number of genes included in the pathway, nominal p-
value, FDR adjusted q-value and adjusted p-value control-
ling for the family-wise error rate. Initially, all 13,850 genes
were ranked according to SAM score, and from this rank-
ing the GSEA score for the pathway was computed. The
significance of the GSEA score was assessed by randomly
permuting gene labels 2000 times and a family wise p-
value was computed, correcting for the 8 pathways tested.
For the GSEA enrichment plot for the down-regulated
“Regulation of Cell Cycle” Pathway, all 13,850 genes
were ranked in descending order based on the Signifi-
cance Analysis of Microarrays (SAM) score comparing
four treated mice vs. four control mice (horizontal heat-
map). The GSEA enrichment score for the pathway
(genes indicated as vertical bars) is indicated as the max-
imal excursion of the green line. This pathway has 41
genes; however one gene was filtered out due to low ex-
pression. Because the pathway is down regulated, the
core enrichment subset consists of the right-most 18
among the 41 expressed genes in the pathway.
Quantitative PCR analysis
The following primers were used in reactions run with
SYBR: BCR-ABL Forward: ctccagactgtccacagcat, BCR-
ABL Reverse: ccctgaggctcaaagtcaga, HPRT Forward:
cgtcttgctcgagatgtgatg, HPRT Reverse: tttatagccccccttg
agcac. Relative levels of mRNA were determined ac-
cording to standard curves. All values were then nor-
malized to HPRT or RPL27 values from the samesample. TaqMan primer/probe sets (ABI) for FoxM1
(Mm00514924_m1), Gli1 (Mm00494645_m1), Gli2
(Mm01293117_m1), Mycn (Mm00476449_m1), Ptch1
(Mm00436026_m1), Ptch2 (Mm00436047_m1), Sfrp1
(Mm00489161_m1), Smo (Mm01162710_m1) on the
ABI 7900HT instrument. Target gene expression levels
were normalized to GAPDH and to vehicle treated mice
to yield the relative quantitation (RQ) value. Expression
qRT-PCR arrays (SA biosciences) were also utilized to
quantify SHH pathway gene expression.
Stromal co-culture assays
Normal or BC CML CD34+ cells were plated on con-
fluent mitomycin-C treated SL/M2 cells with vehicle,
PF-04449913 (1uM), dasatinib (50nM), or combination
treatment. Mouse bone marrow stromal cell lines, M2-
10B4 (M2) and SL/SL (SL) (Stem Cell Technologies
Inc, Vancouver, British Colombia) were treated with
mitomycin-C (1 mg/ml) and plated in a 1:1 mixture at a
total concentration of 100,000 cells/ml one day prior to co-
culture with 10,000-20,000 CD34+ BC CML or normal pro-
genitors. After 1 week of culture, progenitors were FACS
sorted into hematopoietic progenitor assays and colonies
were scored at 14 days as previously described [14]. To as-
sess survival of normal human hematopoietic stem and pro-
genitor cells, irradiated (20 Gray) OP9 (M2 clone) stromal
cells were co-cultured with 50,000 human CD34+ cord
blood cells, vehicle or PF-04449913 in AlphaMEM (Gibco)
with 20% Hyclone FBS, 1% pen strep glutamine and supple-
mented with 50 ng/ml SCF, 10 ng/ml thrombopoietin, and
10 ng/ml Flt3 and quantified by weekly FACS analysis.
Normal and leukemia stem cell xenograft assays
Neonatal immunocompromised RAG2−/−c−/− mice were
transplanted intrahepatically with equal numbers of normal
progenitors or BC LSC as previously described [42]. Upon
detection of human CD45+ cell peripheral blood engraft-
ment, mice were treated daily by oral gavage with vehicle
(50% 1,2 Propandiol, 50% HBSS or methylcellulose), PF-
04449913 (100 mg/kg), Dasatinib (50 mg/kg), or the com-
bination for 14 days followed by FACS to quantify human
engraftment in hematopoietic niches. To assess effects on
normal HSC function, 7 to 10 week old NOD.Cg-
PrkdcSCID IL2R1Wjl/SzJ mice were sublethally irradiated,
transplanted retro-orbitally with 100,000 CD34+ human
cord blood cells and treated 8 weeks later with vehicle or
PF-04449913 (100 mg/kg) for 14 days followed by FACS
engraftment analysis.
Confocal fluorescence microscopic and nanoproteomic
GLI2 analysis
Human BC LSC xenografted mouse spleens were em-
bedded in OCT freezing media (Sakura, Torrance, CA)














































































































































































































HHIP 4.95E-14 0.0004 0.0003
CRIM1 3.68E-10 1.83E-06 N/S
WNT11 0.001 1.72E-05 N/S
GLI2 0.049 1.83E-12 0.008
SMO N/S 0.002 N/S
PRKY N/S 0.007 N/S
HHAT N/S 0.028 1.31E-02
MTSS1 N/S N/S 2.61E-02
































































Figure 1 (See legend on next page.)
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Figure 1 SHH pathway deregulation in chronic myeloid leukemia progression. a. Principal components plots derived from RNA-Seq data
for 41 genes in the SHH pathway, from 7 chronic phase (CP; blue triangles) and 6 blast crisis (BC; red circles) untreated subjects, as well as 3 cord
blood normal samples (CB; black diamonds) and 3 normal peripheral blood (NPB; black circles). b. Heatmap from unsupervised agglomerative
hierarchical clustering of sonic hedgehog (SHH) pathway genes using RNA-Seq data from FACS-purified progenitors (CD34+CD38+lin−PI−) from 8
chronic phase (CP) and 9 blast crisis (BC) patients, 3 normal cord blood (CB) and 3 normal peripheral blood (NPB) sample. Samples labeled in bold
correspond to patients that received clinical BCR-ABL inhibitor therapy. Red indicates over- and green, under-expression relative to the median
RPKM (Log2 scale). Grey represent not expressed (RPKM = 0). c. Network analysis performed on differentially expressed genes between BC and CP
revealed GLI2 as a key hub in the SHH pathway. d. Differentially expressed (DE) SHH genes at FDR 5% when comparing Blast crisis (BC) versus
chronic phase (CP) or normal (CB and NPB). e. Box plots for GLI2 expression of 7 chronic phase (CP) and 6 blast crisis (BC) non-treated subjects, as
well as 3 cord blood normal samples (CB) and 3 normal peripheral blood (NPB). Two-sided Jonckheere-Terpstra trend test: p = 0.014. f. GLI1 and
GLI2 transcripts were compared using quantitative RT-PCR in FACS-purified human cord blood and normal peripheral blood CD34+CD38+Lin−PI−
progenitor cells (n = 9, black), chronic phase CML (n = 7, blue) and in blast crisis CML (n = 10, red) patient derived samples. Values were normalized
to RPL27 or HPRT housekeeping genes, and set to 1 for the normal progenitors. (Student’s t-test *p < 0.05).
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Serotec) antibodies followed by mounting with Prolong®
Gold antifade with DAPI (Invitrogen). Confocal fluores-
cence images were acquired using an Olympus Fluoview
FV10i microscope. Nanofluidic phospho-proteomic im-
munoassay (NPI) experiments were performed in triplicate
with the Nanopro 1000 instrument (Cell Biosciences). After
separation and photo-activated in-capillary immobilization,
GLI2 was detected using a GLI2-specific antibody (Abcam).
A β2-microglubulin-specific antibody (β2M; Upstate) was
used to normalize the amount of loaded protein. The
peaks were quantified by calculating the area under the
curve (AUC).
Cell cycle FACS analysis
Single cell suspensions of bone marrow cells from LSC
xenografted mice treated with vehicle or PF-04449913,
were immunostained with Alexa647-conjugated anti-
human CD45 (BioLegend) and the LIVE⁄DEAD® stain
(Invitrogen). Cells were then immunostained with FITC-
conjugated anti-Ki-67 (Abcam, 1:100) in 0.15% saponin/
2% fetal bovine serum/PBS and incubated with 7- AAD
(10 μg/mL in 0.1 M sodium citrate/5 mM EDTA
pH8.0/0.15 M NaCl/0.5% BSA/0.02% saponin) followed
by FACS Aria analysis.
Statistical analysis
Statistical analyses for pre-clinical studies were per-
formed with Microsoft Excel and Graphpad Prism soft-
ware. Continuous variables for each comparison group
were assessed for distribution through univariate statis-
tics. If the assumption of normal distribution could be
supported, then the Student’s t test was performed for
comparison of two samples with assessment of equality
of variance with an F statistic. If the assumption of nor-
mal distribution was not supported, nonparametric test-
ing was performed with the two samples Wilcoxon test
using the t approximation for samples with N of less
than 20. Differential gene expression from RNA-Seq data
was detected using R package, DESeq, (v1.4.1) with asignificance threshold at 5% false discovery rate (FDR).
The Wilcoxon test was used for comparing means of
genes expression and identifying genes with significant
fold changes. P-values were corrected for multiple hy-
potheses testing using the Benjamini-Hochberg method.
Unsupervised hierarchical clustering analysis was per-
formed using complete linkage on log2-transformed
RPKM values that were centered on the median.
Results
Hh pathway deregulation signifies human leukemic
progression and LSC generation
To determine whether distinctive Hh pathway gene ex-
pression patterns predict CML progression, we utilized
RNA-seq to compare expression levels of 41 a priori se-
lected Hh pathway genes [19-21,45,46] in chronic phase
(CP, n = 8), blast crisis (BC, n = 9), normal cord blood
(CB, n = 3) and normal peripheral blood (NPB, n = 3)
FACS-purified CD34+CD38+Lin− progenitors (Additional
file 1: Table S1 and S2). Principal component analysis
(PCA) and unsupervised hierarchical clustering revealed
distinctive expression level differences among 41 Hh path-
way genes that significantly (p = 0.047, permutation test)
separated normal from untreated CP and BC progenitors
and BCR-ABL inhibitor treated samples (Figure 1a, b).
The expression levels of 20,613 genes above detectable
expression levels (RPKM > 0.2 in over 75% of samples)
were compared between untreated CP (n = 7) and BC
(n = 6) progenitors. Among 1,495 differentially expressed
(DE) genes (FDR < 0.05), key SHH genes were included
(Figure 1d). Notably, a GLI2 network was enriched in BC
LSC for upregulated DE genes using Ingenuity software
(Figure 1c). Both RNA Seq (Figure 1e) and qRT PCR
(Figure 1f ) analyses confirmed significantly increased
expression of the SHH pathway transcriptional activa-
tor, GLI2, during BC transformation. Together these
data suggest that critical regulatory components of the
Hh signaling pathway, such as GLI2, represent part of a
core transcriptional program driving human myeloid
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Figure 2 (See legend on next page.)
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Figure 2 Selective shh inhibition reduces lsc burden in stromal co-cultures. a. Chemical structure of PF-04449913, a selective smoothened
(SMO) antagonist. b. FACS analysis revealed a significant (Student’s t-test, *p = 0.047) reduction in blast crisis leukemic progenitor survival (n = 4
patient derived samples) following 7 days of PF-04449913 (1 μM, purple) compared with vehicle (DMSO, blue) treatment in SL/M2 co-cultures.
c. Cord blood (n = 3) CD34+ cells were plated on SL/M2 co-cultures and treated with vehicle (DMSO) or PF-04449913 (1uM) for 7 days. Colony
forming unit (CFU) survival was determined and compared to vehicle treatment. d. Spleen weight in blast crisis CML LSC engrafted mice after
14 days of treatment with vehicle (n = 16, blue) or PF-04449913 (n = 12; 100 mg/kg daily, purple). A significant (Student t-test, *p = 0.006) reduction is
observed after PF-044449913 treatment. e. Nanoproteomic (CB1000) traces of total GLI2 protein of CD34 + CD38+ FACS sorted derived from the spleen of
mice (n = 5) after vehicle (blue) or PF-04449913 (green) treatment for 14 days with 100 mg/kg daily. f. GLI2 expression was determined after normalizing
the area under the curve (AUC) to a β2-microglobulin (β2M) loading control (Student’s t-test *p = 0.001) g. Confocal fluorescence microscopic analysis of
spleen sections from no transplant or LSC engrafted mice treated with vehicle or PF-04449913. Photomicrographs of sections stained with DAPI and
antibodies specific for human CD45, human GLI2 and the merged image.
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tagonist to eradicate LSC.
Selective SMO inhibition reduces GLI2-expressing LSC
burden in supportive niches
A clinical small molecule SMO antagonist, PF-04449913
(Figure 2a), which was shown to compete for binding to
human SMO (amino acids 181–787) with an IC50 of 4 nM
(Additional file 1: Figure S1a), was utilized in this study,
which is know to reduce GLI expression. PF-04449913
inhibited sonic hedgehog (Shh) stimulated luciferase ex-
pression in mouse embryonic fibroblasts with an IC50 of
6.8 nM (Additional file 1: Figure S1b, c); and significantly
reduced medulloblastoma growth in a Ptch1+/−p53+/− allo-
graft model (Additional file 1: Figure S1d, e) at doses that
decreased murine Shh target gene expression (Additional
file 1: Figure S1f-h). To recapitulate extrinsic growth
regulatory cues provided by the LSC niche, human BC
CML progenitors were co-cultured on human SCF, IL-3
and G-CSF secreting (SL/M2) stromal layers. In stromal
co-culture experiments, FACS analysis demonstrated a
significant reduction in BC LSC (Figure 2b) by PF-
04449913 when compared with normal progenitors and
(Figure 2c). Importantly, human BC LSC engrafted
RAG2−/−γc
−/− mice treated daily with PF-04449913
compared with vehicle treated controls had a significant
spleen weight reduction (p = 0.006) (Figure 2d). This
reduction in leukemic burden corresponded with de-
creased GLI2 protein expression, as determined by both
nanoproteomic analysis of FACS purified human pro-
genitors (Figure 2e, f ) and GLI2 confocal fluorescence
microscopic analysis of splenic sections (Figure 2 g).
While some studies suggest that Hh signaling is dispens-
able for normal mouse hematopoiesis [40], others demon-
strate that GLI regulates hematopoietic stem cell (HSC)
fate decisions [47]. However, the role of Hh signaling in
normal human HSC and progenitor cell maintenance had
not been examined extensively in vitro or in primary sam-
ple xenograft models that permit robust engraftment. Thus,
we compared the effects of PF-04449913 and vehicle treat-
ment on normal hematopoietic stem and progenitor cellsand demonstrated no change in differentiation capacity
(Additional file 1: Figure S2a). When CD34+ cord blood
engrafted NSG mice were treated with PF-04449913, the
frequency of human CD45+ cells, progenitors and both
myeloid and lymphoid cell fate commitment remained
comparable to vehicle treated controls (Additional file 1:
Figure S2b-d) indicating that unlike LSC, normal human
HSC cell fate decisions are Hh pathway independent [41].
These results highlight the important niche dependent ef-
fects of selective SMO inhibition that induce GLI2 down-
regulation in a cell type and context specific manner.
GLI2 induces cell cycle arrest in leukemic progenitors
Because LSC in the G0 phase of the cell cycle are consid-
ered dormant and typically resistant to therapies that tar-
get dividing cells and GLI transcriptional regulators have
been implicated in cell cycle regulation, the role of GLI2
in LSC dormancy was examined. To this end, a lentiviral
vector expressing full length human GLI2 was generated.
As the key Hh pathway transcriptional activator, GLI2 is a
167 kDa protein that binds DNA through its zinc finger
domain. To determine if GLI2 transcriptional activity is
required to induce LSC dormancy, a GLI2 deletion mutant
lacking the transactivation domain (GLI2ΔTAD) was gen-
erated (Figure 3a). Deletion of the transactivation domain
of GLI2 inhibits GLI2 specific transcriptional activity [48].
In addition, both Western blot and immunoprecipitation
analyses were used to validate GLI2 lentiviral vectors in
293A cells (Figure 3b). To determine if GLI2 induces LSC
dormancy, chronic phase (CP) CML primary patient sam-
ple (n = 5) derived progenitors were transduced with back-
bone vector, GLI2, or GLI2ΔTAD lentiviral vectors and
co-cultured on SL/M2 LSC supportive stroma [13]. To de-
termine lentiviral GLI2 transduction efficiency in CML
progenitors, Q-RT-PCR using GLI2 specific primers was
employed. Multicolor cell cycle FACS analysis performed
on these CML progenitors (Figure 3c) demonstrated an
increase in the G0 population in samples transduced at
high transduction efficiency with GLI2 compared to vector
and GLI2ΔTAD. Notably, Spearman correlation analysis
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Figure 3 GLI2 induces cell cycle arrest in leukemic progenitors. a. Both the lentiviral GLI2 wild-type (GLI2) and transactivation domain deleted
(GLI2 ΔTAD) expression constructs contain an N-terminus Flag epitope tag. The scheme depicts both wild type and mutant GLI2. GLI2 ΔTAD mutant
harbors a deletion of the transactivation domain reported in [48]. b. Western blot of 293A cells transduced with GLI2 and immunoprecipitated using flag
epitope. c. FACS based cell cycle analysis of patient samples (CD45+) that had either been transduced with vector, wild type (GLI2), or mutant (GLI2).
d-e. Spearman correlation analysis comparing GLI2 expression levels, determined by quantitative PCR, and percent of cells in G0 after lentivital GLI2 or GLI2
ΔTAD compared with backbone vector controls.
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GLI2 transduced CP primary samples (n = 7, p = 0.024) in
contrast to GLI2ΔTAD transduced samples, which did not
expand the G0 fraction (n = 7; p = 0.84) (Figure 3e).SMO inhibition abrogates LSC dormancy in vivo
To determine whether myeloid leukemic progression was
associated with cell cycle pathway deregulation, we com-
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NAME SIZE NOM p-val FDR q-val
REGULATION OF CELL CYCLE 41 9.76E-04 0.040042
G1 PHASE AND G1/S TRANSITION 12 0.142568 0.413871
G2 PHASE AND G2/M TRANSITION 23 0.174927 0.408327
KEGG_CELL_CYCLE 121 0.110553 0.317688
CELL CYCLE CHECKPOINT AND CELL CYCLE ARREST 30 0.508577 0.729359
S PHASE AND DNA REPLICATION 9 0.645545 0.828316
M PHASE 7 0.799209 0.841371






Figure 4 (See legend on next page.)
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Figure 4 Shh inhibition induces cycling of dormant leukemic progenitors. a. Heatmap from patient samples, unsupervised agglomerative
hierarchical clustering of cell cycle pathway genes using RNA-Seq data from FACS-purified progenitors (CD34+CD38+lin−PI−) from 8 chronic phase (CP)
and 9 blast crisis (BC) patient samples. Bold indicates prior treatment before sample collection (Additional file 1: Table S1). Red indicates over- and green,
under-expression relative to the median RPKM (Log2 scale). Grey represents no expression. b. Network analysis of BC and CP progenitors revealed CDKN1A
and CDKN2A as cell cycle hub. c. Representative FACS plots in bone marrow CD45+ cells after 14 days of vehicle or PF-04449913 treatment. d. Cell cycle
analysis of bone marrow from BC CML engrafted mice after 14 days of vehicle (n = 4) or PF-04449913 (n = 4). Student’s t-test *p < 0.05 for both G0` and
G1 population compared with vehicle treatment. e. GSEA analysis summary table obtained from RNA sequencing data comparing PF-04449913 treated
engrafted mice (n = 4) to control (n = 4) (average 24.7-58.0 million mapped reads/sample). “Regulation of Cell Cycle” pathway was significantly decreased
in PF-04449913 purified human progenitors derived from treated mice (family-wise p value =0.02). f. GSEA enrichment plot of “Regulation of Cell Cycle”
pathway gene expression following in vivo LSC treatment with PF-04449913. The horizontal heatmap shows SAM score in descending order for all 13,850
genes (SHH pathway genes indicated as vertical black bars). g. Normalized gene expression values for the 18 genes in the core enrichment subset from
the “Regulation of Cell Cycle” pathway. All the genes had a negative SAM score and are sorted in order of descending SAM score along the x-axis. This
order agrees with the order in the GSEA enrichment plot, where expression levels for these genes are significantly reduced in the PF-04449913
treated mice.
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supervised agglomerative hierarchical clustering analysis
demonstrated that distinctive cell cycle gene expression
patterns distinguished BC from CP samples (Figure 4a). In-
genuity pathway analysis revealed increased expression of
cell cycle regulatory genes, such as CDKN1A and 2A, indi-
cative of cell cycle arrest in BC progenitor LSCs (Figure 4b).
Because dormancy gene induction could promote thera-
peutic resistance and relapse following TKI or chemother-
apy discontinuation [49], we assessed the capacity of the
SMO inhibitor, PF-04449913, to eradicate human BC LSC
in xenograft studies. While PF-04449913 treatment in-
creased the G1 fraction, it reduced the therapy resistant
G0 fraction (Figure 4c, d). To elucidate a potential mech-
anism of cell cycle activation following selective SMO in-
hibition in vivo, RNA-seq was performed on surviving
progenitors hematopoietic tissues that were FACS purified
from hematopoietic tissues following treatment of hu-
man LSC engrafted mice (Additioanal file 1: Table S3).
Significant repression of cell cycle regulators (family
wise p-value 0.02) was observed in response to PF-
04449913 treatment (Figure 4e-g). These experiments
revealed that cell cycle induction in LSC represents a
novel mechanism for the loss of LSC maintenance fol-
lowing SMO inhibition.
GLI2 inhibition enhances LSC cycling and TKI sensitivity
Having observed the reduction in dormancy following
SMO inhibition, we investigated whether PF-04449913
sensitized BC LSC to dasatinib (Figure 5a) - a potent
BCR-ABL TKI that targets dividing cells. Engrafted mice
treated with a combination of PF-04449913 and dasatinib
showed a significant reduction (p < 0.01, ANOVA) in mye-
loid sarcoma formation (Figure 5b) as well as in both bone
marrow LSC burden (p < 0.05, ANOVA) (Figure 5c) and
BCR-ABL1 (p < 0.05, ANOVA) expression (Figure 5d).
Furthermore, quantitative RT-PCR Hh array analysis of
FACS-purified progenitors revealed significantly (p = 0.05,
Limma method) increased expression of negative Hhpathway regulators, including NUMB, PRKACB, FKBP8,
CSNK1A1 and CSNK1D (Figure 5e) following combin-
ation therapy. Serial transplantation experiments demon-
strated a significantly reduced capacity of LSC to form
myeloid sarcomas (p < 0.01, ANOVA) following PF-
04449913 and dasatinib therapy (Figure 5f). This study
has provided the impetus for the on-going Phase 1b/ll
combination SHH inhibitor and TKI inhibitor clinical tri-
als for patients with advanced myeloid malignancies to
both halt progression and prevent relapse.
Discussion
RNA-Seq gene expression analyses of functionally vali-
dated LSC in advanced human myeloid malignancies,
such BC CML, demonstrate that activation of stem cell
self-renewal and survival pathways signifies therapeutic
resistance that could translate into poor clinical out-
comes. These studies suggest that LSC profiling may
represent an important patient prognostication strategy.
Current evidence also suggests that deregulated stem
cell dormancy, survival and self-renewal pathway activa-
tion leads to malignant reprogramming of progenitors
into LSC that drive therapeutic resistance, relapse and
myeloid leukemia progression [2,7,15,50-52]. However,
selective and clinically effective dormant human LSC
eradication strategies have remained elusive.
Because SMO signals primarily through GLI2, we hy-
pothesized that selective SMO inhibition would reduce
the dormant LSC burden particularly when combined
with TKIs. Indeed, SMO treatment enhanced TKI sensi-
tivity and inhibited LSC self-renewal in stromal co-
culture and LSC xenograft models at doses that spared
normal hematopoietic stem and progenitor cells. More-
over, SMO inhibition enhanced BC LSC sensitivity to a
potent BCR-ABL1 inhibitor, dasatinib, leading to a re-
duction in self-renewal capacity. These studies suggest
that cell cycle induction in dormant LSC in conjunction
with targeted therapy may prevent leukemic persistence








































































































































































































14-day treatment (n=8 experiments):
     Vehicle       31
     PF-04449913       25
     Dasatinib         27
     PF-04449913 + Dasatinib      27
8.5 weeks
Hematopoietic Tissue FACS Analysis,
number of Myeloid Sarcomas and
qRT-PCR (panels b, c, d & e)
Number of Myeloid Sarcomas (panel f)
Self Renewal
Figure 5 PF-04449913 induced cell cycle activation enhances TKI sensitivity. a. Schematic of in vivo experiments. RAG2−/−γc
−/− pups were
transplanted intrahepatically with 50,000 CD34+ BC CML cells within 48 hours of birth. Engrafted mice were treated daily for 14 days by oral gavage with
vehicle, PF-04449913 (100 mg/kg), Dasatinib (50 mg/kg) or the combination. b. Graph of myeloid sarcoma count in blast crisis CML engrafted mice in
vehicle (n =13, blue), PF-04449913 (n=7, purple), dasatinib (n =6, red) and combination (n =3, black) treated mice +/− SEM; *p < 0.05 and *p < 0.01 by
ANOVA and Tukey post-hoc analysis c. FACS analysis showing percentage of marrow engrafted blast crisis progenitor LSC (n = 3 patients) after 14-day
treatment with vehicle (n =31, blue), PF-04449913 (n =25, purple), dasatinib (n =27, maroon) and combination (n=27, grey). *p < 0.05 by ANOVA
and Tukey post-hoc analysis d. BCR-ABL transcripts in the blast crisis CML engrafted marrow mice after 14 days of treatment. Graph shows
normalized BCR-ABL expression (HPRT) +/− SEM; *p < 0.05 by ANOVA and Tukey post-hoc analysis e. Hedgehog pathway gene expression in
FACS purified human progenitor cells from blast crisis LSC engrafted mouse marrow treated with vehicle (n = 3, blue), PF-04449913 (n = 4,
purple) dasatinib (n = 4, maroon), combination (n=3, dark grey). Expression levels of seven genes were significantly altered by synergistic effect
of PF-04449913 and Dasatinib (NUMB, PRKACB, CTNNB1, FKBP8, CSNK1A1, CSNK1D and STK36), where five represent SHH regulatory genes
(graphed). f. Mice serially transplanted with FACS purified human progenitors from LSC engrafted mice treated with vehicle (n=12, green),
PF-04449913 (n=12, purple), dasatinib (n = 8, maroon) or combination (n=7, grey) were examined for myeloid sarcomas; *p < 0.05 and
*p < 0.01 by ANOVA and Tukey post-hoc analysis.
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apeutic resistance have been identified in other myeloid
malignancies, such as AML. A recent study demonstrated
that GLI alone is sufficient to drive UGT1A-dependent
glucuronidation of Ara-C in AML thereby leading to drug
resistance. This resistance was overcome by genetic or
pharmacologic inhibition of GLI using a SMO antagonist
[35]. Based on recent advances in leukemia clinical trials
showing promise of a variety of molecular therapies, the
key to eradicating an evolving population of cells lies in
combination therapies that selectively inhibit multiple tar-
gets. Ideally, these targets will be specifically activated inthe LSC compartment, and pharmacological inhibition
will spare normal adult stem cells during the course of
treatment.
While selective reduction in LSC self-renewal capacity
provides strong pre-clinical evidence for a direct LSC in-
hibitory effect, the potential capacity of PF-04449913 to
modify the malignant niche may also contribute to its
anti-leukemic efficacy and will need to be examined in
clinical correlative studies in ongoing clinical trials.
Moreover, the clinical importance of SMO inhibitor me-
diated sensitization of dormant LSC to therapeutic mo-
dalities that target dividing cells will need to be assessed
Sadarangani et al. Journal of Translational Medicine  (2015) 13:98 Page 13 of 14in Phase 2 clinical trials. Overall, our results inform the
development of a clinically tractable strategy for obviat-
ing therapeutic resistance by selective SMO inhibitor
targeting of dormant leukemia stem cells alone or in com-
bination with standard of care in advanced hematologic
malignancies.
Conclusions
Our work addresses the role of smoothened (SMO) acti-
vation of its downstream hedgehog pathway transcrip-
tional activator, GLI2, in human myeloid leukemia
progression, leukemia stem cell self-renewal and dor-
mancy. RNA-Seq, nanoproteomic and qRT-PCR analyses
of FACS purified progenitors revealed that distinctive
expression patterns of both SHH and cell cycle regula-
tory genes, including GLI2cpg CDKN1A and CDKN2A,
were harbingers of myeloid leukemic progression and
LSC generation. Because of the niche dependency of Hh
pathway signaling, the capacity of a selective SMO an-
tagonist, PF-04449913, to inhibit human LSC was evalu-
ated in stromal co-cultures and in various hematopoietic
tissues in xenografts models. In these systems, LSC bur-
den decreased commensurate with GLI2 and cell cycle
regulatory gene repression and while GLI2 overexpres-
sion enhances dormant human leukemia stem cell gen-
eration, selective inhibition of SMO abrogates it and
sensitizes them to tyrosine kinase inhibitors. While lenti-
viral overexpression of human GLI2 enhanced CML
progenitor dormancy in stromal co-culture assays, the
transcriptionally inactive form of GLI2 did not. In
addition, cell cycle FACS analysis revealed a reduction in
dormant LSC following PF-04449913 treatment in all
hematopoietic niches. Our data suggest that GLI2 repre-
sents part of a core transcriptional program driving hu-
man myeloid LSC maintenance thereby providing the
rationale for clinically assessing the capacity of a se-
lective SMO antagonist alone or in combination with
anti-proliferative agents to eradicate dormant therapy
resistant LSC in advanced myeloid malignancies.
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